CA1309402C

CA1309402C - Heparin derivatives and process for their preparation

Info

Publication number: CA1309402C
Application number: CA000602338A
Authority: CA
Inventors: Marinella Fantuz; Silvano Piani; Gianfranco Tamagnone; Raul Roberto Alpino; Maria Rita Milani
Original assignee: Alfa Wasserman SpA
Current assignee: Alfa Wasserman SpA
Priority date: 1988-06-10
Filing date: 1989-06-09
Publication date: 1992-10-27
Anticipated expiration: 2009-10-27
Also published as: NO174259B; NO892366L; FI892850A0; FI94534B; IT1234508B; AU611028B2; JPH0264102A; IE64830B1; NO892366D0; DE68917040D1; EP0347588B1; PT90817A; GR900300018T1; PT90817B; NO174259C; DK173818B1; FI94534C; IE891762L; DE347588T1; ATE109164T1

Abstract

ABSTRACT

New heparin derivative having antithrombotic activity, also endowed with reduced hemorrhagic and anticoagulant effects, obtained by treating in a basic medium heparins of various origin, optionally in the presence of alkali metal salts and of a reducing agent.

The heparin derivatives obtained through this treat-ment show peculiar chemico-physical characteristics, like new signals at about 53 and 54 p.p.m. in the 13C-NMR
spectrum and a raise of the specific rotatory power, compared to that of the starting heparins, to values between +50° to +90°.

Said structural modifications produce an improvement of the biological properties of the heparin, substantially keeping the antithrombotic activity while diminishing the hemorrhagic effect in vivo and the anticoagulant activity in vitro.

Description

1309402 ~

~_CKGROUND OF THE INVENTION

The pre~ent invention refer~ to new heparin derivatives having antithrombotic activity, al90 endowed with reduced hemorrhagic and anticoagulant effects, obtained by treating in a basic medium heparins of variou~
origin, optionally in the presence of alkali metal salt~
and of a reducing agent.
It i~ known that heparin~ll~e structures can be modified in various manners by treating them in a basic medium.
In European Publication EP 013307~, Mardiguian J.S., depolymerizes the heparin into oligosaccharideq fractions containing from 4 to 20 saccharides units, by treating the benzyl ester of the heparin by means of an organic or inorganic base, at a concentration between 0.1 and 0.6 molar at a temperature between 20C and 80C. Such depolymerization i8 accompanied by the formation of a double bond in the positions 4 and 5 of the uronic acid, detectable by U.V. absorption at 230 nm.
Hirano S. et _1., Conn. Tissue Res., 3, 73-79, 1975 depolymerize the heparin and other glycosaminoglycans in -strong basic medium, by using from 2 to 10 molar concentra-tions of sodium or barium hydroxlde at temperatures higher than 30C. In this way they get a strong depolymerization followlng the cleavage of the glucosidic bond between the posltion 1 of glucosamine uni~ and the position 4 of ad~acent uronic unit~, moreover suoh depolymerization is accompanied by the formatio,n of a double bond in the positions 4 and 5 of the uronic acld, detectable by mean3 of an absorption at 225-230 nm in the U.V. spectrum.
Samp~on P. and Meyer K., Proc. Nat. Acad. Sci. USA, 68, 2329-~331, 1971, obtained a structural modlfication in the gluco~amine unit with formation of 3,6-anhydro-glucosamine by treating heparin with lN sodium hydroxide in the presence of sodium borohydride at 80C for 7 hours.l The heparin derivatives ob~ect of the present inven-tion totally differ from those described in the prior art. In fact they do not show the chemico-physical properties of the compounds obtained by Mardiguian J.S. and by Hirano S. et _1.. as it is ~hown by the average molecular weight which remains substantially unchanged, ~o proving the lack of depolymerization, and by the lack of absorption at 225-230 nm in U.V. and of peaks corresponding to the resonances of the double bond in the l~C-NMR, lndexes of the lack of the double bond in the positions 4 and 5 of the uronic acid. Moreover they do not even ~how the chemico-phy~ical properties of the compounds isolated by Sampson P. and Meyer K. as the ~aC-NMR spectrum of the compounds obtained in the present invention shows unchanged the posltion and the intenslty of the slgnal of the carbon atom in positlon 6 of the glucosamine and shows unchanged "`'` .

the inten~ity ratio between the 6-~ulfated carbon atom and the 6-desulfated carbon atom that ~hould change in case of formation of 3,6-anhydroglucosamine becau~e of the participation of the 6-sul~ated carbon atom in the formation of the anhydroderlvatlve.

SUMMARY OF THE INVENTION

The present invention refers to new heparin deriva-tives, to their therapeutic use in the treatment of the thrombotic pathologies and to the proces~ for their preparation by mean~ of a chemical modification made in baslc aqueous medium, optionally in the presence of salts and of a reducing agent, on heparins of various origin, commercial or purified by means of suitable treatments or depolymerized.
The new compounds having a modified heparinic structure possess chemico-physical properties, like ~pecific rotatory power and '~C-NMR peaks, dif~erent from those of the starting compounds and also present a different biological activity as they show a better action specificity as they keep practically unchanged the anti-thrombotic properties while the hemorrhagic effect and the anticoagulant power are lowered. In particular they are characterized by the fact that they 3how two new signals in the 'JC-NM~ spectrum at about 53 and 54 ppm and a raise of the specific rotatory power, with respect to the ~tarting heparlns, with values between about +50 and about +90 in aqueous solution.
The chemical modification of the heparinic structure i9 obtalned in aqueous medium at pH values higher than neutrality in the presence of a base, preferably of an alkali or an alkali-earth metal hydroxide, optionally in the presence of an alkali or alkali-earth metal salt and of a reducing substance, preferably sodium borohydride.
The reaction i9 carried out for a period of time between 0.5 and 24 hours, at a temperature between about 35C and about 70C, using base concentrations between about O.OlN and about lN and salt concentrations between 0 and about lN, optionally in the presence of a reducing substance, like, for in~tance, sodium borohydride.
Alkali or alkali-earth metal bases and salts are preferably used, mainly those of sodium, potas~ium, calcium, magnesium and barium.
The hydroxides of sodium, potassium and barium are the bases that can be advantageously used.
The acetates and chlorides of sodium, potassium, barium, calclum and magnesium and the sulfates of sodium, potassium and magneslum are the salts that can be advantageously used.
~ he process of modification of the heparinic structure is carried out by dissolving the heparinic material ln an ~309402 aqueous solutlon from about O.OlN to about lN of a base of an alkali or alkall-earth metal, optionally in the pre~ence of a salt of an alkali or alkali-earth metal, at a concen-tration lower or equal than lN, and of a catalytic amount of a reducing agent, and by thermostating the ~olution at a temperature between about 35C and about 70C for a period of time between about 0.5 hours and about 24 hour~.
At the end of the reaction the solution i~ cooled to room temperature, brought to neutral pH and optionally purified, for instance by means of ion exchange resins or of dialysis, and la~tly the modified heparin derivative i8 precipitated by adding from about 2 to about 4 volumes, preferably 2.5 volumes, of an alcohol containing from 1 to 3 carbon atoms, like for instance ethyl alcohol.
The modified heparins obtained in this process ~how ~ome peculiar chemico-phy~ical characteristics which are totally different from tho~e coming from the alkali t~eatments known from the prior art. This iB due to the reaction conditions used in the present invention where the values of the parameter~, mainly as regards the base concentration, the temperature and the optional presence of a salt, are significantly different from those previouqly uYed .
The ~tructural changes of the new heparin derivatives have been principally shown from the position and the relative intensity of the resonances in the ~JC-NMR

130940~:

3pectrum and also from the electrophoretic behaviour, from the raise of the value~ of the specific rotatory power and from the decrea~e of the sulfur content and of the sulfates/carboxyls ratio, belng unchanged the carboxyls content.
The more characteri~tic changes in the structure of the new heparin derivative~ have been checked through the study of the deep changes occurred in the ~C-NMR spectrum.
These variations refer to some specific zones of the spectrum and involve both the appearance of new peak~ and the modification of other peaks. Of noteworthy importance is the appearance of two new signals at about 53 and about 54 ppm and the shlfts of the peak~ corresponding to the carbon atom 1 of the iduronic and glucosaminic unit in the zone between 92 ppm and 102 ppm. The comparative check of the ~C-NMR spectra of the new compounds and of those of the starting compounds enable u~ to establish that some zones of the spectrum are unchanged and that consequently some portion~ of the heparinic ~tructure have not been modified at all. In particular, the signals related to the position 6 of the sulfated or desulated glucosamine unit have not been modified. Moreover, the peak~ related to the position 2 of the glucosamine units, sulfated or acetylated, to the carboxy group of the iduronic acid and to the units of glucuronic acid, which in the heparin form an average of the 20X of the uronic residues, are unchanged.

The chemico-phy~ical characteri~tlc~ of the new heparin derivatives result the more modified the more drastic are the reaction conditions, as it can be inferred from the not limiting descrlbed examples. Therefore the modulatlon of the parameter~ of the reaction makes possible the obtaining of compounds more or less deeply modified in their structure.
The amount of the chemical modification can be calculated by doing the ratio between the sum of the integral~ of the peaks at about 53 and about 54 ppm and the sum of the integrals of the peaks of the carbon atom in the position 6 of the glucosamine unit, at about 62.5 and about 69 ppm, these latter being selected as an arbitrary reference because their intensity remains stable and because they are in a spectrum zone free from other peaks.
Parallelly to the raise of the re~onances at about 53 and about 54 ppm there i8 an increase of the rotatory power at 689 nm (D llne of sodium) and therefore the measurement of the ~pecific rotatory power can be directly used for the evaluation of the degree of the chemical modification occurred in the heparinic ~tructure. A~ optically active reagents are not used in the reaction medium, the measure-ment of the rotatory power can be directly used for the check of t'he cour~e of the reaction.
Both the ratios of the integrals of the peak of the ~ 3C-NMR and the increase of the specific rotatory power 1~0~402 in respect of the ~tarting compound are reported in the following table 1.

Area of peak~ Difference amony the at 53 and 54 ppm specific rotatory powers EXAMPLE ~ --------------- of the modiied and Area of peaks the starting heparins at 62.5 and 69 ppm [~ ] D~ -________________________________________________________ _____ 0.15 + 5a 6 0.25 + 7 7 0.30 + 7 4 0.4s ~ 10 1 0.55 + 1a 2 0.75 + 22 3 1.20 + 29 ______________________________________________________________ These modified heparin~ are moreover characterized in that they possess a different electrophoretic behaviour from that of the startlng compounds, characterlzed by a qreater mobility in barium acetate buffer 0.lM at pH 5. a ~P. Oreste, G. Torri, J. Chrom. 195, 398, (1980)], and in that they have a sulfur content between about a% and about llX, a sulfates/carboxyls ratio between about 1.50 and about 2.20 and a specific rotatory power ~ ~ ~D between about +50 and about +90 as it is shown by the following ~309402 table 2 w~ere, 1n brackets, the value~ of the correspondlng starting compounds are reported.

____________________________________________________________ EXAMPLE X ~ulfates sulfates/carboxyls [~ ]D

ratio ____________________________________________________________ 510.31 (11.40) 2.17 ~2.27) +50 (+45) 610.69 (11.60) 2.15 (2.32) +54 ~47) 79.70 tll.00) 1.90 (2.00) +51~ (+44) 49.65 (10.56) 2.03 (2.20) ~57 (+47) 18.95 (10.56) 1.94 (2.20) ~65~ (+47~
28.42 (10.09) 1.64 (2.13) +65 (+43) 38.12 (10.09) 1.55 (2.13) ~72 (+43) __ _____ ____________________________________ ______________ The new h~parin derivatives, ob~ect of the present invention, pos3ess a marked antithrombotic activity together with a lower anticoagulant effect in re~pect of the atarting heparins. Their biological activity was assessed through many typical tests of the heparins; precisely the tests of the antl-Xa factor, of APTT, of the bleeding time and of the protection from the experimental throm~osis were carried out. The APTT activity was determined according to the method of Larrieu M.J. and Weiland G., Rev.
Hematol., 12, 199, (1957), while the anti-Xa activity was determined according to the method of Yin E.T. and Wessler S., Biochem. Biophys. Acta, 201, 387, (1970).
Every examined compound was dlssolved in plasma taken from fasting ratq, then proportional dilutionq were made to obtain the concentrations provided for by the met~od. Ten determinations were performed for both activities for each compound and the quantity that causes a higly significant change in the corresponding te~t was calculated in mcg/ml. In particular, the activity of each product was expres~ed as the concentration, in mcg/ml, that respective-ly doubles the APTT time and that increases the anti-Xa value of 30%. The values obtained in the two te~ts ~ee table 3) confirm that the new compounds show a diminution of the anticoagulant power.
The bleeding time was carried out in the rat accord-ing to the method described by De~ana E. et al, Thromb.
Haemost., 48, 108, 1982 and the result was expressed by calculatlng the percent of the time of the bleeding elongation in the rats treated with the new heparins in comparison with the time of bleeding elongation in the rats treated with the corre~ponding starting heparins considered e~ual to lOOX. All the new derivatives having modified heparinic structure, ob~ect of the present invention, showed a decrease, often very marked, of the bleeding time, in comparison with the corresponding starting heparins.
The antithrombotic activity was assessed by the test 130940~:

of the sta~is venous thrombosis descri~ed by Reyers S. et al. Thromb. Res. 18, 669-74, 19~0. The protection afforded by the new compounds was calculated, in percent, by taking equal to 100 the antithrombotic protectlon given by the starting heparins.
The obtained results ~howed a substantial equivalence of the two ~eries of heparins as regards this test on the antithrombotic activity.
The value~ of the a~ove described biological tests are summarized in the following table 3 where the anti-Xa and the APTT values of the corresponding starting heparins are reported within brackets.

_____________________________________________________________________________ Antl-Xa Actlvlty APTT Actlvlty Uco~lng tl~o.
Amount of com- Antithrombotic EXAHPLE pound which Amount of com- % Elongation in protection S in increa~e~ pound which compari~on with compari~on with the anti-Xa doubles the the ~tarting the startinq value of 30% APTT time heparinic heparinic (mcg/ml) ~mcg/ml) material material _____________________________________________________________________________ 1 30.2 t20.6)4.2 (1.7) 22 100 2 33.7 tl8.6)B.9 (1.9) 83 117 3 43.5 ~lB.6)16.3 (1.9) 11 53 4 lB.l (20.6)4.B (1.7) 60 75 21.0 (16.5)11.5 (10.8) 9 113 6 44.0 (40.6)B.B (8.5) 30 113 7 19.6 (1~.2)2.6 (2.0) 30 88 ____________________________________________________________________________ ~30gflO2 In v~ew of the above seen pharmacological propertles, these new heparin derivatives a~e u~eful for treating thrombotic pathologies. The preferred way~ of administra-tion are the parenteral and the subcutaneous ones in form of sterile aqueou~ solution~, optionally containing al90 some salts, ln order to make the solutlon isotonic, and some preserving agents.
The dosage range depends on the used pharmaceutical formulations and on the state of the patient; in a preferred way, an amount of heparin derivative, according to the present invention, equivalent to between 5,000 and 20,000 Units of anti-Xa factor (U.A.Xa) i3 administered one or more times a day.
As the starting ~ubstrates, heparinic materials of different origin can be employed. For example, commercial heparins and heparins purified by treatment of commercial heparins, as well as low molecular weight heparins, obtalned by depolymerizatlon according to methods known in the art, were employed in order to get the modified heparins ob~ect of the present invent~on. Underneath, we show the preparation of the starting heparinic materials used in the present invention.

Sodium heP_rin ALFA 87-78 Grams of commercial sodium heparin are dissolved in 2000 ml of water and poured in about 30 minutes into a solution containing 111.2 g of calcium acetate monohydrate ~309~0;~
in 2000 ml of water, 57 ml of acetic acld and 600 ml of ethyl alcohol, while keeping the temperature at about B,10C. The obtained ~u~pension i9 filtered after hour~ at 5C and the filtrate iJ added with 1000 ml of ethyl alcohol and after 3 hours at 5C the obtained precipitate i9 filtered. The precipitate i9 then dl~olved in 200 ml of water, the ~olution iq brought to ph 7.0 by mean~ of sodium hydroxide lN and then it i8 treated with 100 ml of Dowex 50W XB, sodium form, resin and with 70 ml of water for 20 minute~. Solution and resin are transferred into a chromatograpphic column ~ = 1.6 cm, h = 10 cm) containing 80 ml of the ~ame resin. After having percolated the solution and eluted it with di~tilled water until a total volume of ~olution equal to 400 ml, ~aid solution i8 added with 12 g of ~odium acetate trihydrate and with 1000 ml of ethyl alcohol. The precipitate i~ filtered and dried under vacuum obtaining 19.2 g of purified ~odium heparin named ALFA B7-78 having the following chemico-phy~ical characteristic~:
S = 10.09 X, ~ulfate~/carboxyls ratio = 2.13, = ~43 (C = 1% in H~0) 1JC-NMR ~pectrum tppm): 177.3; 104.7; 102.0; 99.4; 80.0;
78.6; 72.3; 71.9; 69.0; 62.5; 60.6.

S_d_um heParin ALFA 87 81 It wa~ obtained by mean~ of the 3ame method of purification uqed for ALFA 87-78 ~tarting from 50 g of the /7~(~/c ~/~ - 14 -same commerclal heparln.
36,5 Gram~ of purified heparin were obtained having the following chemico-physical characteristics:
S = 10,56%; ~ulfate~/carboxyls ratlo = 2.20 tJ~]~ = + 47 tC = lX in H~O) ~3C-NMR spectrum (ppm~: 177.3; 104.7; 102.0; 99.S; 80.1;
78.6; 72.4; 72.0; 69.1; 62.7; 60.7.

Commercial sodium heparin _ ___ _ ______ _ _ _ It is a heparin having the following chemico-physical characteristic~:
S = ll.OX; sulfate~/carboxyls ratio = 2 t~ ]D = ~ 44 (C = lX in H~O) 13C-NMR spectrum (ppm): 177.4; 104.6; 101.9; 99.8; 79.9;
78.6; 72.2; 71.8; 69.0; 62.6; 60.6.

Low molecular weiqht sodium h~E_rin LMW ALFA 86-02 The low molecular welght ~odium heparin LMW ALFA B6-02 was prepared by depolymerization with hydrogen peroxide in pre~ence of cupric ions according to the method described in the international patent publication WO 86/06729.
It shows the following chemico-physical characteristics:
average molecular weight: 4200 daltons, S = 11.40%; sulfate~/carboxyls ratio = 2.27 t~ ]b = + 45 (C = 1% in H~0) ~3C-NMR spectrum (ppm): 177.4; 104.6; 101.9; 99.B; 79.9;

13~9402 78.6; 72.6; 72.2; 71.9; 69.1; 62.7; 60.7.

L_w m_le_ul__ weight sod_um hep__in LMW ALFA B7-198 The low molecular weiyht sodium heparin LMW ALFA o7~198 was prepared by depolymerization according to the method used for LMW 86-02.
It ~hows the following chemlco-phy~ical characterlstlcs:
S = 11.60X; sulfates/carboxyl~ ratio = 2.32 ~] ~ = + 47 (C = 1% in H~0) ~3C-NMR spectrum (ppm): 177.7; 104.8; 102.0; 99.6; 80.2;
78.6; 72.4; 71.9; 69.2; 62.7; 60.6.

The determination of the values of the specific rotatory power [~ ~ D was carried out in aqueous medium at a concentration of lX.
The determination of the sulfate~/carboxyls ratio was executed by potentiometric way.
The determination of the sulfur percentage was carried out both with the potentiometric method and with the Schoeniger method.
The ~aC-NMR spectra were executed at 75.47 MHz with a Varian CFT-75 spectrometer by using D,0 as ~olvent and sodium 3-trimethyl~ilylpropansulfonate a~ reference internal ~tandard.

!

The following examples have to be considered as an explanation of the present inventlon and not a~ an it~
limitation.
~ ~C~c ~ - 16 ~

1.8 Grams of heparin ALFA 87-81 are added to 45 ml of an aqueous solution containing 0.4 g of sodium hydroxide ~0.225 N), 2.3 g of sodium acetate ~0.625 N) and 10 mg of sodium borohydrlde. The obtalned solutlon 19 thermostated at 60C for 3.5 hours, then it 18 cooled to room tempera-ture, brought to neutrality with glacial acetic acid and added with 2.5 volumes of ethanol. The precipitate i3 filtered, washed on the filter wlth a 6:1 ethanol/water mlxture and dried. 1.7 Gram~ of product are obtained having a 9C-NMR spectrum that shows characteristic signals at the following S ~expressed as ppm): 177.3; 104.3; 101.9;
99.4; 98.4; 97.2; 96.8; 79.7; 79.1; 78.5; 72.1; 71.8; 71.2;
68.8; 62.4; 60.6; 60.3; 54.1; 53.1.

~ 1.8 Grams of heparin ALFA 87-78 are added to 45 ml of an aqueous solution containing 0.4 g ~0.225 N) of sodium hydroxlde, 2.3 g of sodium acetate (0.625 N) and 10 mg of sodlum borohydride. The solution is thermostated at 60G
for 15 hours and, after cooling, it is brought to neutrality with acetic acid and then it is percoled thru a column (~ = 1.2 cm, h = 8 cm) containing Dowex~1 X 2, chloride form, anionic resin. The percolate and the washings are collected together and added with 2.5 volumes of ethanol.
The precipitate i8 flltered, washed on the filter with a ~c~ - 17 -i30g402 6:1 ethanol~water mlxture and drled. 1.65 Grams of product are obtained having a 1~C-NMR spectrum that shows characteristic signals at the following ~ (expre~sed as ppm): 177.4; 104.6; 101.8; 98.6; 97.2; 96.8; 79.6; 79.1;
78.9; 72.2; 71.5; 71.2; 68.~; 62.5; 60.3; 54.1; 53.1.

1.8 Grams of heparin ALFA 87-78 is added to 120 ml of an aqueou~ solution containing 4.8 g (1 N) of sodium hydroxide. The solution i~ thermostated at 60C for 3.5 hours, brought to neutrality with acetic acid and dialyzed for one night with running water and for 6 hour3 with distilled water. The solution is then added wi~h 3.5 g of sodium acetate, brought to neutrality with acetic acid and added with 2.5 volumes of ethanol. The precipitate is filtered, washed with a 6:1 ethanol/water mixture and dried. 1.7 Grams of product are obtained havlng a ~aC-NMR
spectrum that shows characteristic peaks a the following ~ (expressed a~ ppm): 177.4; 104.6; 101.7; 98.6; 98.4;
97.2; 96.8; 79.7; 79.1; 78.6; 73.5; 72.5; 72.3; 72.1; 71.5;
68,8; 62.6; 60.4; 60.2; 54.0; 53.1.

E3~AMpr.F _ 4 Gram~ of heparin ALFA 87-81 are added to 120 ml of an aqueous ~olution containing 4.8 g (1 N) of sodlum hydroxide, 6.2 g (0.625 N) of sodium acetate and 25 mg of ~30g402 ~odium borohydride. The reaction mixture is thermostated at 60C for 3.5 hour~, then it i9 neutralized with acetic acid, dialyzed for 24 hour~ with running water and percolated thru a Dowex*l X 4, chloride form, anionic re~in ~Y = 1.6 cm, h = 15 cm). The percolate and the wa~hings are added with 4 g of sodium acetate and 2.5 volume~ of ethanol. The precipitate i3 filtered and washed on the fllter with a 6:1 ethanol/water mixture and dried.
3.55 Grams of product are obtained having a '3C-NMR
spectrum that show~ characteristic peaks at the following ~ (expre~sed a~ ppm): 177.4; 104.5; 101.B; 99.4; 98.7;
97.1; 79.5; 78.6; 73.5; 71.8; 6~.8; 62.4; 60.3; 54.0; 53.1.

1.8 Grams of heparin LMW ALFA 86-02 are added to 50 ml of an aqueous solution containing 0.08 g (0.04 N) of sodium hydroxide, 2.6 g (0.625 N) of sodium acetate and mg of ~odium borohydride. The reaction mixture i8 thermo~tated at 60~C for 210 minutes, then it i~ cooled to room temperature and i9 percoled fir~t on a column of anionic resin Dowex lX4, OH- form (~ = 1.2 cm, h = 10 cm) and then on a column of cationic resln Dowex 50 WX8, H~
form ~ = 1.2 cm; h = 10 cm). The percolate and the washings are brought to neutrality by means of a 2 N
aqueous solution of sodium hydroxide and then are added with 4 g of sodium acetate and with 2.5 volumes of ethanol.

~L J7~:7/G ~'~ 9 130940~

The obtained precipltate i9 wAsh~d wlth a 6 : 1 ~thanol/
water mixture and dried. 1.4 Gra~ of product are obtained having a ~JC-NMR spectrum that shows characteristic peaks of the following cs (expressed as ppm): 177,4; 104.6;
101.9; 99.4; 98.6; 98.4; 97.2; 96.8; 79.9; 7B.6; 72.3;
71.9; 68.~; 62.6; 60.~; 54.1; 53.1.

Gram~ of heparin LMW ALFA B7-198 are added to 300 ml of an aqueous ~olution containing 2.7 g ~0.225 N) of ~odium hydroxide, 15 g (0.625 N) of sodium acetate and 60 mg of sodium borohydride. The solution is thermostated at 60C for 50 minutes, cooled to room temperature, diluted to 500 ml with di~tilled water and percoled first on anionic resin Dowex~l X 2, OH- form (~= 2 cm;
h = 15 cm) and then on catlonic resin Dowex 50 W X 8, H~
form ~ = 2 cm; h - 15 cm). The percolate and the wa~hing~
aré brought to neutrality by means of a 4 N aqueou~
solution of sodium hydroxide and then are added with 20 of ~odium acetate and 2.5 volumes of ethanol. The obtained precipitate i~ washed with a 6 : 1 ethanol/water mlxture and dried. 9.1 Grams of product are obtained having a 'JC-NMR ~pectrum that ~how~ characteristic peaks at the following ~ (expre~ed as ppm): 177.4; 104.6; 101.9; 99.8;
98.6; 98.4; 97.2; 96.8; 79.8; 78.6; 72.2; 71.8; 68.9; 62.5;
60.3; 54.1; 53.1.

f J~radc rh~

~309~02 Grams of commercial sodium heparin are added to 600 ml of an aqueous solution containiny 5.4 g (0.225 N) of sodium hydroxide, 30 g ~0.625 N) of sodium acetate and 120 mg of sodium borohydride. The solution i~ thermo- -stated at 42C for 4 hours, cooled at room temperature and brought to neutrallty with acetlc acid. The solution i~
dialyzed for one night with runnlng water and.then is percoled on a column of anionic resin Dowex lX2, chloride form (~ = 2.8 cm; h = 15 cm). The percolate and the washings are added with 10 g of sodium acetate, brought to pH 7 by means o a 2 N aqueous ~olution of sodium hydroxide and added with 2.5 volumes of ethanol. The obtained precipitate i9 washed with a 6 : 1 ethanol~water mixture and dried. 13.9 Grams of product are obtained having a ~'C-NMR spectrum that shows characteristic peaks at the following ~ (expressed as ppm): 177.3; 104.6; 101.9;
99.8; 98.6; 9a.4; 97.2; 96.B; 79.9; 78.6; 72.2; 71.8; 69.0;
62.5; 60.3; 54.1; 53.1.

A vial for parenteral use contains:
- heparln modified according to Example 1. . . 10.000 U.A.Xa - F.U. sodium chloride F.U. . . . . . . . . . 5 mg - B.P 8enzyl alcohol. . . . . . . . . . . . . ~ mg - bldistilled sterlle water. . . . . . . . . . 1 ml ~ ~q~e ~ - 21

Claims

1) New heparin derivatives characterized by signals in the 13C-NMR spectrum at about 53 and about 54 ppm, specific rotatory power between about +50° and about +90° in aqueous solution, sulfur content between about a% and about 11% and sulfates/carboxyls ratio between about 1.50 and about 2.20.

2) Process for the preparation of new heparinic derivatives characterized by signals in the 13C-NMR spectrum at about 53 and about 54 ppm, specific rotatory power between about +50° and about +90° in aqueous solution, sulfur content between about 8% and about 11% and sulfates/carboxyls ratio between about 1.50 and about 2.20, which comprises treating an aqueous solution of a heparinic material with a base of an alkali or alkali-earth metal at a concentration between about 0.01 N and about 1 N, in the presence of a concentration between 0 and about 1 N of a salt of an alkali or an alkali-earth metal, facultatively in the presence of a catalytic amount of a reducing agent, for a period of time between 0.5 and 24 hours at a temperature between about 35°C and about 70°C, optionally purifying the reaction mixture by percolation thru a ionic exchange resin or by dialysis, and precipitating the compounds having the so modified structure by adding from about 2 to about 4 volumes of an alcohol containing from 1 to 3 carbon atoms at a pH

about neutral.

3) Process according to claim 2 wherein the base is select-ed among sodium, potassium and barium hydroxides.

4) Process according to claim 2 wherein the salts are selected among the sodium, potassium, barium, calcium and magnesium chlorides and acetates and the sodium, potassium and magnesium sulfates.

5) Process according to claim 2 wherein the reducing agent is the sodium borohydride.

6) Process according to claim 2 wherein the compounds are precipitated by adding about 2.5 volumes of ethyl alcohol.